- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
39 result(s) found for: Mass balance.
Displaying page 1 of 2.
EudraCT Number: 2014-001545-25 | Sponsor Protocol Number: CHDR1409 | Start Date*: 2014-07-02 | ||||||||||||||||
Sponsor Name:Centre for Human Drug Research | ||||||||||||||||||
Full Title: Randomized, double-blind, placebo-controlled, three way crossover, double dummy, single centre study evaluating the effect of haloperidol 2 mg and lorazepam 1 mg on posturography and underlying sys... | ||||||||||||||||||
Medical condition: Healthy volunteers (balance disorders) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002568-18 | Sponsor Protocol Number: 5B | Start Date*: 2015-07-15 |
Sponsor Name:Stockholm County Council, Karolinska University Hospital Huddinge, Department of Anesthesiology and Intensive Care | ||
Full Title: Albumin mass balance and kinetics in liver transplantation. An open exploratory pilot study | ||
Medical condition: liver transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002487-41 | Sponsor Protocol Number: GLY-321-2017 | Start Date*: 2018-01-31 | |||||||||||
Sponsor Name:GLyPharma Therapeutic Inc. (a wholly owned subsidiary of VectivBio Holding AG) | |||||||||||||
Full Title: A Phase Ib/IIa open-label, repeated dose, metabolic balance study of FE 203799 in patients with short bowel syndrome | |||||||||||||
Medical condition: Short bowel syndrome (SBS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003898-26 | Sponsor Protocol Number: 516-007 | Start Date*: 2019-12-23 | |||||||||||
Sponsor Name:Mirati Therapeutics, Inc. | |||||||||||||
Full Title: A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO ASSESS THE MASS BALANCE, ROUTE OF ELIMINATION, AND METABOLIC PROFILE OF [14C] LABELED MGCD516 MALATE SALT IN HEALTHY MALE SUBJECTS | |||||||||||||
Medical condition: Cancer/oncology | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004350-91 | Sponsor Protocol Number: TAK-375/EC301 | Start Date*: 2005-11-10 | |||||||||||
Sponsor Name:Takeda Europe R&D Centre Ltd | |||||||||||||
Full Title: A multicentre, randomised, double-blind, double-dummy, placebo-controlled study to evaluate the safety and efficacy of ramelteon compared to placebo with zopiclone as a reference arm in adults with... | |||||||||||||
Medical condition: chronic insomnia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) AT (Completed) FI (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004979-39 | Sponsor Protocol Number: MSP-2017-1220 | Start Date*: 2020-08-06 |
Sponsor Name:Milestone Pharmaceuticals Inc. | ||
Full Title: An open-label, mass balance study to investigate the absorption, distribution, metabolism and excretion of [14C]-etripamil nasal spray after a single dose to healthy male subjects | ||
Medical condition: Paroxysmal supraventricular tachycardia (PSVT) | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-006577-30 | Sponsor Protocol Number: D4326C00003 | Start Date*: 2022-09-21 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Two Part Phase IIa/b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and... | |||||||||||||
Medical condition: Liver cirrhosis with features of portal hypertension. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) AT (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001250-41 | Sponsor Protocol Number: KOLD | Start Date*: 2015-04-15 |
Sponsor Name:Region Östergötland | ||
Full Title: THE IMPACT OF VITAMIN D ON PHYSICAL TRAINING OF VITAMIN D DEFICIENT PATIENTS WITH COPD: A PROSPECTIVE RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTI-CENTRE STUDY | ||
Medical condition: Patients with chronic obstructive pulmonary disease (COPD) and concomitant vitamin D deficiency | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001220-19 | Sponsor Protocol Number: D5670C00021 | Start Date*: 2018-08-07 | |||||||||||
Sponsor Name:MedImmune Limited, a wholly owned subsidiary of AstraZeneca | |||||||||||||
Full Title: An Exploratory Phase 2a, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects with Type 2 Diabetes Mellitus | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000043-31 | Sponsor Protocol Number: 383 | Start Date*: 2020-03-26 |
Sponsor Name:Groupe Hospitalier Paris Saint-Joseph | ||
Full Title: Efficacy and tolerance of Liraglutide for weight loss in obese type 2 diabetic hemodialysis patients | ||
Medical condition: obese type 2 diabetic hemodialysis patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003495-39 | Sponsor Protocol Number: Debio-0932-102 | Start Date*: 2012-10-08 | |||||||||||
Sponsor Name:Debiopharm SA | |||||||||||||
Full Title: A Two-Part, Sequential Design Study to Determine Debio 0932 Absolute Oral Bioavailability, Mass Balance Recovery, Metabolite Profiling and Structural Identification in 3 Cohorts of Healthy Male Sub... | |||||||||||||
Medical condition: Debio-0932 is currently under development for the treatment of cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004978-34 | Sponsor Protocol Number: RBHP2017BACHOUMAS | Start Date*: 2018-12-04 |
Sponsor Name:CHU de Clermont-ferrand | ||
Full Title: Efficacy of Testosterone gel to restore normal serum values of testosterone during the acute phase of critical illness in adult ICU patients. An open-label parallel randomized controlled pilot study | ||
Medical condition: - Hypermetabolism in ICU, loss of muscle mass and functional disability after ICU - ICU acquired hypogonadism - Treatment with testosterone gel in ICU | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000585-41 | Sponsor Protocol Number: OG-061-01 | Start Date*: 2020-11-06 | ||||||||||||||||
Sponsor Name:T-Balance Therapeutics GmbH | ||||||||||||||||||
Full Title: Effects of tregalizumab on allergen-induced airway responses and airway inflammation in asthmatic patients | ||||||||||||||||||
Medical condition: mild controlled allergic asthma and house-dust mite (HDM) allergy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000649-30 | Sponsor Protocol Number: P150905 | Start Date*: 2016-09-29 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Impact of the administration of Fludrocortisone the fluid and electrolyte balance in great premature. Pilot study. | |||||||||||||
Medical condition: Great prematurity | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002080-88 | Sponsor Protocol Number: NA | Start Date*: 2005-09-13 | |||||||||||
Sponsor Name:Aintree Hospitals NHS Trust and University of Liverpool | |||||||||||||
Full Title: A double−blind, placebo−controlled crossover trial to quantify the effects of sibutramine on energy intake and energy expenditure in obese subjects during a test meal | |||||||||||||
Medical condition: Obesity defined as BMI > 30 kg /m2 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000362-39 | Sponsor Protocol Number: CSPP100A2243 | Start Date*: 2005-06-22 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomized, double-blind, parallel-group, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the renoprotective effect of renin inhibition with Aliskiren as an a... | ||
Medical condition: Hypertension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004122-18 | Sponsor Protocol Number: 2012GR12 | Start Date*: 2014-12-12 | |||||||||||
Sponsor Name:University of Dundee, Tayside Clinical Trials Unit | |||||||||||||
Full Title: A Prospective Study to Evaluate the Effect of Allopurinol on Muscle Energetics in Older People with Impaired Physical Function. | |||||||||||||
Medical condition: FUNCTIONAL IMPAIRMENT | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004467-50 | Sponsor Protocol Number: SFN-3-2019 | Start Date*: 2021-05-19 | ||||||||||||||||||||||||||
Sponsor Name:University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro | ||||||||||||||||||||||||||||
Full Title: The effects of SGLT2-inhibition in patients with non-diabetic chronic kidney disease on renal hemodynamics, kidney function and vasoactive hormones | ||||||||||||||||||||||||||||
Medical condition: Chronic Kidney Disease | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004447-80 | Sponsor Protocol Number: SFN-2-2019 | Start Date*: 2021-05-19 | |||||||||||||||||||||||||||||||
Sponsor Name:University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro | |||||||||||||||||||||||||||||||||
Full Title: The effects of SGLT2-inhibition in patients with type 2 diabetes and chronic kidney disease on renal hemodynamics, kidney function and vasoactive hormones | |||||||||||||||||||||||||||||||||
Medical condition: Type 2 diabetes with chronic kidney disease | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-000057-20 | Sponsor Protocol Number: HC-G-H-1209 | Start Date*: 2015-11-10 | ||||||||||||||||
Sponsor Name:B. Braun Melsungen AG | ||||||||||||||||||
Full Title: PROSPECTIVE, RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTI-CENTRIC, INTERNATIONAL, STUDY ON THE EFFICACY AND SAFETY OF AN EARLY TARGET CONTROLLED PLASMA VOLUME REPLACEMENT THERAPY WITH A BALANCED GEL... | ||||||||||||||||||
Medical condition: Hypovolaemia in Severe Sepsis / Septic Shock | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Completed) AT (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
